1. Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol. 2010;75(3):173–234.
2. Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression – implications for drug resistance. Nat Rev Clin Oncol. 2013 Oct;10(10):571–87.
3. Young RC, Canellos GP, Chabner BA, Schein PS, DeVita VT. Maintenance chemotherapy for advanced Hodgkin’s disease in remission. Lancet. 1973;1(7816):1339–43.
4. Alexanian R, Gehan E, Haut A, Saiki J, Weick J. Unmaintained remissions in multiple myeloma. Blood. 1978;51(6):1005–11.
5. Cara S, Tannock IF. Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol. 2001;12(1):23–7.